NCT07139899Recruiting
Downstream Effects of Airway Mucus Plugs on 129Xenon MRI in Severe Asthma
Downstream Effects of Airway Mucus Plugs on 129Xenon MRI Following Biologic Therapy
Source: ClinicalTrials.gov · Last updated 20 Nov 2025
Brief summary (registry, in English)
In this study, xenon MRI will be used to evaluate regional functional consequences of mucus plugs in the lungs of patients with severe asthma. Mucus plugs will be identified using CT imaging, and xenon MRI will be used to evaluate ventilation and gas exchange impairments in regions of the lungs corresponding to the airways downstream of mucus plugs.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 5 (estimated)
- First submitted
- 18 Aug 2025
- Start date
- 17 Nov 2025
- Primary completion date
- Nov 2026
- Lead sponsor
- Bastiaan Driehuys
- Diseases
- Asthma
- NCT number
- NCT07139899
What you commit to
- Study type: Observational
- Planned participants: 5
- From 17 Nov 2025 to the primary completion date, Nov 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Respiratory tract infection within the 4 weeks prior to Visit 1
- One-time doses such as intra-articular injections require a 4-week washout prior to Visit 1
- Asthma-related ER visit within the previous 4 weeks of Visit 1 or at any time while on the study
- Significant concomitant medical illness, including (but not limited to) heart disease, cancer, uncontrolled diabetes, other chronic lung diseases (determined by the Investigator.)
- Participation in an intervention study (including bronchoscopy) or use of investigative drugs within the past 30 days or plans to enroll in such a trial during the study
Other illness
- Conditions that will prohibit MRI scanning determined by the MRI safety screening.
Other
- Body mass index (BMI) \> 30 at Visit 1
- Resting O2 saturation \<90% with maximum supplemental O2 delivered by nasal cannula
- Positive urine pregnancy test at Visit 1 or at any time while on the study
- Unable or unlikely to complete study assessments in the opinion of the Investigator
- Study intervention poses undue risk to patient in the opinion of the Investigator
Who the study is looking for
- Adequate completion of informed consent process with written documentation
- Patients 18 - 65 years old
- Physician diagnosis of asthma for \> 1 year
- Able to perform reproducible spirometry according to ATS criteria based on clinical PFTs within previous 30 days of enrollment
- All racial/ethnic backgrounds may participate
- Blood eosinophil count \> 300 cells/μL
- Smoking history \<10 pack years
- No smoking history (including vapes, cigar, or marijuana use) in the last 3 months
- About to initiate asthma therapy with either dupilumab, tezepelumab, or benralizumab as part of their standard of care
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Duke University Medical Center Coordinator of this site? Confirm its status | Durham | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.